Brochure | March 1, 2022

LentiVector® Platform

Bioprocess Bioreactor Cleanroom GettyImages-532549174

Oxford Biomedica’s LentiVector® platform, the first and leading commercial lentiviral-based gene delivery system, enables the successful development of breakthrough gene and cell-based medicines.

We have a long and broad clinical and commercial track record in the gene therapy field spanning over 20 years. Our data demonstrates over seven years of stable, dose dependent gene expression in patients after direct in vivo administration. Thousands of patients have safely received ex vivo and in vivo treatment with therapies that use our vectors.

Our LentiVector® platform has delivered the first FDA and EMA approved CAR-T cell therapy.

VIEW THE BROCHURE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: